First Therapy for Non-metastatic, Castration-resistant Prostate Cancer Patients Approved in US

First Therapy for Non-metastatic, Castration-resistant Prostate Cancer Patients Approved in US
The U.S. Food and Drug Administration (FDA) approved Johnson & Johnson’s Erleada (apalutamide), a next-generation androgen receptor inhibitor, as therapy for patients with localized (non-metastatic) prostate cancer who failed to respond to hormone therapy. This makes Erleada the first FDA-approved therapy for non-metastatic, castration-resistant prostate cancer. The decision was supported by results from SPARTAN (NCT01946204), a

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *